{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:54:14Z","timestamp":1792713254814,"version":"4.5.0"},"reference-count":206,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2015,3,2]],"date-time":"2015-03-02T00:00:00Z","timestamp":1425254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Histone dacetylases (HDACs) are a group of enzymes that remove acetyl groups from histones and regulate expression of tumor suppressor genes. They are implicated in many human diseases, especially cancer, making them a promising therapeutic target for treatment of the latter by developing a wide variety of inhibitors. HDAC inhibitors interfere with HDAC activity and regulate biological events, such as cell cycle, differentiation and apoptosis in cancer cells. As a result, HDAC inhibitor-based therapies have gained much attention for cancer treatment. To date, the FDA has approved three HDAC inhibitors for cutaneous\/peripheral T-cell lymphoma and many more HDAC inhibitors are in different stages of clinical development for the treatment of hematological malignancies as well as solid tumors. In the intensifying efforts to discover new, hopefully more therapeutically efficacious HDAC inhibitors, molecular modeling-based rational drug design has played an important role in identifying potential inhibitors that vary in molecular structures and properties. In this review, we summarize four major structural classes of HDAC inhibitors that are in clinical trials and different computer modeling tools available for their structural modifications as a guide to discover additional HDAC inhibitors with greater therapeutic utility.<\/jats:p>","DOI":"10.3390\/molecules20033898","type":"journal-article","created":{"date-parts":[[2015,3,2]],"date-time":"2015-03-02T10:45:12Z","timestamp":1425293112000},"page":"3898-3941","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":607,"title":["Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents"],"prefix":"10.3390","volume":"20","author":[{"given":"Madhusoodanan","family":"Mottamal","sequence":"first","affiliation":[{"name":"RCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, LA 70125, USA"},{"name":"Department of Chemistry, Xavier University of Louisiana, New Orleans, LA 70125, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-2408","authenticated-orcid":false,"given":"Shilong","family":"Zheng","sequence":"additional","affiliation":[{"name":"RCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, LA 70125, USA"},{"name":"Department of Chemistry, Xavier University of Louisiana, New Orleans, LA 70125, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien","family":"Huang","sequence":"additional","affiliation":[{"name":"RCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, LA 70125, USA"},{"name":"College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangdi","family":"Wang","sequence":"additional","affiliation":[{"name":"RCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, LA 70125, USA"},{"name":"Department of Chemistry, Xavier University of Louisiana, New Orleans, LA 70125, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2015,3,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nature01595","article-title":"The structure of DNA in the nucleosome core","volume":"423","author":"Richmond","year":"2003","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0092-8674(04)00044-3","article-title":"The nucleosome: From genomic organization to genomic regulation","volume":"116","author":"Khorasanizadeh","year":"2004","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev.biochem.70.1.81","article-title":"Histone acetyltransferases","volume":"70","author":"Roth","year":"2001","journal-title":"Annu. Rev. Biochem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","article-title":"Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells","volume":"92","author":"Marks","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jmb.2004.02.006","article-title":"Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis","volume":"338","author":"Gregoretti","year":"2004","journal-title":"J. Mol. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1574-6976.2007.00100.x","article-title":"Histone modifications and chromatin dynamics: A focus on filamentous fungi","volume":"32","author":"Brosch","year":"2008","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1128\/MCB.25.8.2873-2884.2005","article-title":"Class II histone deacetylases: From sequence to function, regulation, and clinical implication","volume":"25","author":"Yang","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1139\/o01-116","article-title":"The emerging role of class II histone deacetylases","volume":"79","author":"Fischle","year":"2001","journal-title":"Biochem. Cell Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jss.2010.12.035","article-title":"Suppression of histone deacetylase 11 promotes expression of il-10 in kupffer cells and induces tolerance following orthotopic liver transplantation in rats","volume":"174","author":"Lian","year":"2012","journal-title":"J. Surg. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/ni.1673","article-title":"The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance","volume":"10","author":"Villagra","year":"2009","journal-title":"Nat. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1182\/blood-2010-08-303701","article-title":"HDAC11 plays an essential role in regulating ox40 ligand expression in hodgkin lymphoma","volume":"117","author":"Buglio","year":"2011","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"11446","DOI":"10.1074\/jbc.M809394200","article-title":"Acetylation\/deacetylation modulates the stability of DNA replication licensing factor cdt1","volume":"284","author":"Glozak","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1006\/bbrc.2000.3000","article-title":"Phylogenetic classification of prokaryotic and eukaryotic sir2-like proteins","volume":"273","author":"Frye","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20070140","article-title":"Sirtuins in mammals: Insights into their biological function","volume":"404","author":"Michan","year":"2007","journal-title":"Biochem. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1474-4422(11)70013-8","article-title":"The sirtuin pathway in ageing and alzheimer disease: Mechanistic and therapeutic considerations","volume":"10","author":"Bonda","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrm3293","article-title":"Sirtuins as regulators of metabolism and healthspan","volume":"13","author":"Houtkooper","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4155\/fmc.14.44","article-title":"Sirtuin inhibitors as anticancer agents","volume":"6","author":"Hu","year":"2014","journal-title":"Future Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2174\/138161209787185742","article-title":"Nad+, sirtuins, and cardiovascular disease","volume":"15","author":"Borradaile","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20295","DOI":"10.3390\/molecules191220295","article-title":"Anticancer agents targeted to sirtuins","volume":"19","author":"Kozako","year":"2014","journal-title":"Molecules"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/ng1531","article-title":"Loss of acetylation at lys16 and trimethylation at lys20 of histone h4 is a common hallmark of human cancer","volume":"37","author":"Fraga","year":"2005","journal-title":"Nat. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-642-21631-2_3","article-title":"Deacetylation of nonhistone proteins by HDACs and the implications in cancer","volume":"206","author":"Peng","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1586\/era.10.62","article-title":"Nonhistone protein acetylation as cancer therapy targets","volume":"10","author":"Singh","year":"2010","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_25","first-page":"166","article-title":"Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Kim","year":"2011","journal-title":"Am. J. Trans. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"Fda approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase ii multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Pohlman, B., Advani, R., Duvic, M., Hymes, K.B., Intragumtornchai, T., Lekhakula, A., Shpilberg, O., Lerner, A., Ben-Yehuda, D., and Hillen, U. (2009, January 5\u20138). Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma. Proceedings of the 51st ASH Annual Meeting and Exposition, New Orleans, LA, USA.","DOI":"10.1182\/blood.V114.22.920.920"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"301","DOI":"10.7164\/antibiotics.47.301","article-title":"Fr901228, a novel antitumor bicyclic depsipeptide produced by chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity","volume":"47","author":"Ueda","year":"1994","journal-title":"J. Antibiot. (Tokyo)"},{"key":"ref_31","unstructured":"FDA approves Beleodaq to treat rare, aggressive form of non-Hodgkin lympoma, Available online: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm403929.htm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/jcb.20532","article-title":"Prospects: Histone deacetylase inhibitors","volume":"96","author":"Dokmanovic","year":"2005","journal-title":"J. Cell. Biochem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.2174\/09298673113209990191","article-title":"A structural insight into hydroxamic acid based histone deacetylase inhibitors for the presence of anticancer activity","volume":"21","author":"Rajak","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/43710","article-title":"Structures of a histone deacetylase homologue bound to the tsa and saha inhibitors","volume":"401","author":"Finnin","year":"1999","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrd772","article-title":"Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer","volume":"1","author":"Johnstone","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-014-1433-2","article-title":"Vorinostat as a radiosensitizer for brain metastasis: A phase i clinical trial","volume":"118","author":"Shi","year":"2014","journal-title":"J. Neurooncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e24468","DOI":"10.1371\/journal.pone.0024468","article-title":"The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway","volume":"6","author":"Sarfstein","year":"2011","journal-title":"PLoS One"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00428-003-0947-3","article-title":"Molecular genetic pathways in various types of endometrial carcinoma: From a phenotypical to a molecular-based classification","volume":"444","author":"Lax","year":"2004","journal-title":"Virchows Arch."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1158\/1535-7163.MCT-12-0933","article-title":"Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer","volume":"12","author":"Ma","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Saelen, M.G., Ree, A.H., Kristian, A., Fleten, K.G., Furre, T., Hektoen, H.H., and Flatmark, K. (2012). Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma. Radiat. Oncol., 7.","DOI":"10.1186\/1748-717X-7-165"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/bjh.12326","article-title":"Phase I study of vorinostat in combination with standard chop in patients with newly diagnosed peripheral T-cell lymphoma","volume":"162","author":"Oki","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10147-011-0348-6","article-title":"Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (gi) cancer in a phase i clinical trial","volume":"18","author":"Doi","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.onc.1210204","article-title":"Discovery and development of saha as an anticancer agent","volume":"26","author":"Marks","year":"2007","journal-title":"Oncogene"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Lane","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: Molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.biopha.2014.01.002","article-title":"Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells","volume":"68","author":"Karthik","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"ref_51","first-page":"219","article-title":"The class I HDAC inhibitor romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis","volume":"10","author":"Robertson","year":"2013","journal-title":"J. Exp. Ther. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3109\/07357907.2012.675382","article-title":"Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumors","volume":"30","author":"Jones","year":"2012","journal-title":"Cancer Investig."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1158\/1078-0432.CCR-13-0095","article-title":"Phase i trial of a new schedule of romidepsin in patients with advanced cancers","volume":"19","author":"Luchenko","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40265-014-0275-8","article-title":"Belinostat: First global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/JTO.0b013e318191520c","article-title":"Phase ii study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma","volume":"4","author":"Ramalingam","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.ejca.2010.02.047","article-title":"Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours","volume":"46","author":"Mackay","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","article-title":"Phase ii study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors","volume":"29","author":"Giaccone","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00277-011-1240-1","article-title":"Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)","volume":"91","author":"Cashen","year":"2012","journal-title":"Ann. Hematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ygyno.2012.02.019","article-title":"A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study","volume":"125","author":"Dizon","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/IGC.0b013e31825736fd","article-title":"Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer","volume":"22","author":"Dizon","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.3109\/10428194.2013.877134","article-title":"A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: A california cancer consortium study","volume":"55","author":"Kirschbaum","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1158\/1078-0432.CCR-14-0968","article-title":"A phase I\/II trial of belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in thymic epithelial tumors: A clinical and translational study","volume":"20","author":"Thomas","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10637-009-9219-7","article-title":"The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines","volume":"28","author":"Ma","year":"2010","journal-title":"Investig. New Drugs"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/CAD.0000000000000122","article-title":"Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells","volume":"25","author":"Savickiene","year":"2014","journal-title":"Anticancer Drugs"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","article-title":"Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies","volume":"24","author":"Heaney","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_66","first-page":"3578","article-title":"Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously","volume":"9","author":"Kelly","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, saha) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.bjc.6603463","article-title":"Cancer biology: Mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor","volume":"95","author":"Richon","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Sholler, G.S., Currier, E.A., Dutta, A., Slavik, M.A., Illenye, S.A., Mendonca, M.C.F., Dragon, J., Roberts, S.S., and Bond, J.P. (2013). PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma. J. Cancer Ther. Res., 2.","DOI":"10.7243\/2049-7962-2-21"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.ejca.2013.05.009","article-title":"Pharmacokinetic\/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454\/PCI-24781) in phase I","volume":"49","author":"Fouliard","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1158\/1078-0432.CCR-08-2714","article-title":"Combining pci-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma","volume":"15","author":"Lopez","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.leukres.2012.03.003","article-title":"Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis","volume":"36","author":"Kantarjian","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/bjc.2011.13","article-title":"Phase I clinical, pharmacokinetic and pharmacodynamic study of sb939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours","volume":"104","author":"Razak","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/pbc.24694","article-title":"A phase i study of histone deacetylase inhibitor, pracinostat (sb939), in pediatric patients with refractory solid tumors: Ind203 a trial of the ncic ind program\/c17 pediatric phase i consortium","volume":"60","author":"Zorzi","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-13-0735","article-title":"First-in-human, pharmacokinetic and pharmacodynamic phase i study of resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors","volume":"19","author":"Brunetto","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-2141.2010.08124.x","article-title":"The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (mm) cells","volume":"149","author":"Meinel","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Walewski, J., Paszkiewicz-Kozik, E., Borsaru, G., Moicean, A., Warszewska, A., Strobel, K., Biggi, A., Hauns, B., Mais, A., and Henning, S.W. (2010, January 4\u20137). Resminostat in Relapsed or Refractory Hodgkin Lymphoma: Initial Results of the Saphire phase II Trial with a Novel Oral Histone Deacetylase (HDAC) Inhibitor. Proceedings of the 52nd ASH Annual Meeting and Exposition, Orlando, FL, USA.","DOI":"10.1182\/blood.V116.21.2811.2811"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Walewski, J., Paszkiewicz-Kozik, E., Warszewska, A., Borsaru, G., Moicean, A., Hellmann, A., Mayer, J., Hauns, B., Mais, A., and Henning, S.W. (2011, January 10\u201313). Final Results of the Phase II Saphire Trial of Resminostat (4sc-201) in Patients with Relapsed\/Refractory Hodgkin Lymphoma. Proceedings of the 53rd ASH Annual Meeting and Exposition, San Diego, CA, USA.","DOI":"10.1182\/blood.V118.21.2675.2675"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e15088","DOI":"10.1200\/jco.2013.31.15_suppl.e15088","article-title":"Resminostat in advanced hepatocellular carcinoma (HCC): Overall survival subgroup analysis of prognostic factors in the shelter trial","volume":"31","author":"Bitzer","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","article-title":"A pilot study of the histone-deacetylase inhibitor givinostat in patients with jak2v617f positive chronic myeloproliferative neoplasms","volume":"150","author":"Rambaldi","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.exphem.2012.10.013","article-title":"Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients","volume":"41","author":"Pedrini","year":"2013","journal-title":"Exp. Hematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2119\/molmed.2011.00020","article-title":"Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat)","volume":"17","author":"Furlan","year":"2011","journal-title":"Mol. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/bjh.12332","article-title":"A phase II study of givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy","volume":"161","author":"Finazzi","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/JTO.0b013e318293d88c","article-title":"A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer","volume":"8","author":"Atmaca","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/bjh.12220","article-title":"A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera\/essential thrombocythaemia myelofibrosis (post-PV\/ET MF)","volume":"161","author":"Mascarenhas","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1007\/s10637-011-9751-0","article-title":"Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to japanese patients with advanced solid tumors","volume":"30","author":"Morita","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1007\/s10637-011-9666-9","article-title":"A phase I study of oral panobinostat (LBH589) in japanese patients with advanced solid tumors","volume":"30","author":"Fukutomi","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2011.38.1350","article-title":"Panobinostat in patients with relapsed\/refractory hodgkin\u2019s lymphoma after autologous stem-cell transplantation: Results of a phase II study","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/leu.2013.325","article-title":"Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent ipss low or int-1 mds patients","volume":"28","author":"Platzbecker","year":"2014","journal-title":"Leukemia"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/ajh.22198","article-title":"Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome","volume":"87","author":"Dimicoli","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1158\/0008-5472.CAN-09-3360","article-title":"CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity","volume":"70","author":"Lai","year":"2010","journal-title":"Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1158\/1078-0432.CCR-14-0570","article-title":"Phase I first-in-human study of cudc-101, a multitargeted inhibitor of HDACS, egfr, and her2 in patients with advanced solid tumors","volume":"20","author":"Shimizu","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Fu, S., Nemunaitis, J.J., Bessudo, A., Bauman, J.E., Hamid, O., Witta, S.E., Dy, G.K., Lai, C., Laliberte, R., and Voi, M. (2012, January 1\u20135). A phase Ib study of CUDC-101, A Multitargeted Inhibitor of EGFR, HER2, and HDAC, in Patients with Advanced Head and Neck, Gastric, Breast, Liver, and Non-Small Cell Lung Cancer. Proceedings of 2012 ASCO Annual Meeting, Chicago, IL, USA.","DOI":"10.1200\/jco.2012.30.15_suppl.e13101"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Voi, M., Fu, S., Nemunaitis, J., Bauman, J., Bessudo, A., Hamid, O., Witta, S., Dy, G., Lai, C., and Laliberte, R. (2012). 590 Final results of a phase Ib study of CUDC-101, a multitargeted inhibitor of EGFR, HER2, and HDAC, in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer. Eur. J. Cancer, 48.","DOI":"10.1016\/S0959-8049(12)72387-0"},{"key":"ref_95","unstructured":"ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.Gov."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00280-011-1762-1","article-title":"A randomized phase II study of two doses of vorinostat in combination with 5-fu\/lv in patients with refractory colorectal cancer","volume":"69","author":"Fakih","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1158\/1078-0432.CCR-10-0547","article-title":"A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors","volume":"16","author":"Fakih","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.4161\/auto.29231","article-title":"Combined autophagy and HDAC inhibition: A phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors","volume":"10","author":"Mahalingam","year":"2014","journal-title":"Autophagy"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s10637-011-9766-6","article-title":"Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination","volume":"30","author":"Millward","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3816\/CLML.2010.n.022","article-title":"Vorinostat plus bortezomib for the treatment of relapsed\/refractory multiple myeloma: A case series illustrating utility in clinical practice","volume":"10","author":"Mazumder","year":"2010","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00280-009-1236-x","article-title":"A phase I\/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-fu-based chemotherapy","volume":"65","author":"Wilson","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e91325","DOI":"10.1371\/journal.pone.0091325","article-title":"Treatment of nasopharyngeal carcinoma cells with the histone-deacetylase inhibitor abexinostat: Cooperative effects with cis-platin and radiotherapy on patient-derived xenografts","volume":"9","author":"Gressette","year":"2014","journal-title":"PLoS One"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/1535-7163.MCT-07-2026","article-title":"Mgcd0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo","volume":"7","author":"Fournel","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2007-10-115873","article-title":"Phase 1 study of the oral isotype specific histone deacetylase inhibitor mgcd0103 in leukemia","volume":"112","author":"Assouline","year":"2008","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e52095","DOI":"10.1371\/journal.pone.0052095","article-title":"Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer","volume":"7","author":"Wang","year":"2012","journal-title":"PLoS One"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2141.2009.07881.x","article-title":"Phase ii study of the histone deacetylase inhibitor mgcd0103 in patients with previously treated chronic lymphocytic leukaemia","volume":"147","author":"Blum","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1200\/JCO.2007.14.5730","article-title":"Phase I study of mgcd0103 given as a three-times-per-week oral dose in patients with advanced solid tumors","volume":"26","author":"Siu","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S1470-2045(11)70265-0","article-title":"Mocetinostat for relapsed classical hodgkin\u2019s lymphoma: An open-label, single-arm, phase 2 trial","volume":"12","author":"Younes","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/bjc.2011.527","article-title":"Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours","volume":"106","author":"Pili","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.2011.38.9411","article-title":"Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy","volume":"30","author":"Witta","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1200\/JCO.2012.43.7251","article-title":"Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor","volume":"31","author":"Yardley","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1158\/1078-0432.CCR-07-1461","article-title":"A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, ms-275, in patients with refractory solid tumors and lymphomas","volume":"14","author":"Gore","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1158\/1078-0432.CCR-10-0738","article-title":"Phase 1 study of valproic acid in pediatric patients with refractory solid or cns tumors: A children\u2019s oncology group report","volume":"17","author":"Su","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1634\/theoncologist.2011-0031","article-title":"A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma","volume":"16","author":"Mohammed","year":"2011","journal-title":"Oncologist"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00280-014-2384-1","article-title":"Phase I study of anti-vegf monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers","volume":"73","author":"Wheler","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00280-012-1986-8","article-title":"Phase i study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer","volume":"71","author":"Chu","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_117","first-page":"5187","article-title":"Effects of valproic acid in combination with s-1 on advanced pancreatobiliary tract cancers: Clinical study phases I\/II","volume":"34","author":"Iwahashi","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.tranon.2014.03.001","article-title":"A phase i protocol of hydralazine and valproic acid in advanced, previously treated solid cancers","volume":"7","author":"Bauman","year":"2014","journal-title":"Trans. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1006489328324","article-title":"Chronic oral administration of ci-994: A phase 1 study","volume":"19","author":"Prakash","year":"2001","journal-title":"Investig. New Drugs"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1016\/S0021-9258(17)44885-X","article-title":"Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin a","volume":"265","author":"Yoshida","year":"1990","journal-title":"J. Biol. Chem."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nchembio.1223","article-title":"Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group","volume":"9","author":"Lobera","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1021\/jo7020532","article-title":"Syntheses and biological activity of amamistatin b and analogs","volume":"73","author":"Fennell","year":"2008","journal-title":"J. Org. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1021\/ol070382e","article-title":"Syntheses of amamistatin fragments and determination of their HDAC and antitumor activity","volume":"9","author":"Fennell","year":"2007","journal-title":"Org. Lett."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2485S","DOI":"10.1093\/jn\/133.7.2485S","article-title":"Inhibition of histone deacetylase activity by butyrate","volume":"133","author":"Davie","year":"2003","journal-title":"J. Nutr."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1128\/MCB.25.5.1608-1619.2005","article-title":"Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas","volume":"25","author":"Duan","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.nut.2009.07.006","article-title":"Butyrate and propionate induced activated or non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating gpr-41\/gpr-43 pathways","volume":"26","author":"Aoyama","year":"2010","journal-title":"Nutrition"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ejca.2008.01.023","article-title":"Effects of fr235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: Role of annexin a1","volume":"44","author":"Petrella","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1124\/jpet.102.042903","article-title":"Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin","volume":"304","author":"Bruwiere","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1074\/jbc.M106699200","article-title":"Apicidin, a histone deacetylase inhibitor, induces apoptosis and fas\/fas ligand expression in human acute promyelocytic leukemia cells","volume":"277","author":"Kwon","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"7553","DOI":"10.1002\/anie.200602047","article-title":"Azumamides a-e: Histone deacetylase inhibitory cyclic tetrapeptides from the marine sponge mycale izuensis","volume":"45","author":"Nakao","year":"2006","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.1021\/jm4008449","article-title":"Total synthesis and full histone deacetylase inhibitory profiling of azumamides a-e as well as beta(2)- epi-azumamide e and beta(3)-epi-azumamide e","volume":"56","author":"Villadsen","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1073\/pnas.98.1.87","article-title":"Potent histone deacetylase inhibitors built from trichostatin a and cyclic tetrapeptide antibiotics including trapoxin","volume":"98","author":"Furumai","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1021\/ja7110064","article-title":"Structure and activity of largazole, a potent antiproliferative agent from the floridian marine cyanobacterium symploca sp.","volume":"130","author":"Taori","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cbi.2014.07.004","article-title":"Spiruchostatin a and b, novel histone deacetylase inhibitors, induce apoptosis through reactive oxygen species-mitochondria pathway in human lymphoma u937 cells","volume":"221","author":"Rehman","year":"2014","journal-title":"Chem. Biol. Interact."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jss.2014.02.042","article-title":"The novel histone deacetylase inhibitor thailandepsin a inhibits anaplastic thyroid cancer growth","volume":"190","author":"Weinlander","year":"2014","journal-title":"J. Surg. Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e73097","DOI":"10.1371\/journal.pone.0073097","article-title":"Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells","volume":"8","author":"Venturelli","year":"2013","journal-title":"PLoS One"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1093\/carcin\/bgn165","article-title":"Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances sp3 binding on the p21waf1 promoter","volume":"29","author":"Nian","year":"2008","journal-title":"Carcinogenesis"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/carcin\/bgh123","article-title":"Diallyl disulfide (DADS) increases histone acetylation and p21(waf1\/cip1) expression in human colon tumor cell lines","volume":"25","author":"Druesne","year":"2004","journal-title":"Carcinogenesis"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.3945\/jn.109.113332","article-title":"Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention","volume":"139","author":"Ho","year":"2009","journal-title":"J. Nutr."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/ml500170r","article-title":"Modulation of activity profiles for largazole-based HDAC inhibitors through alteration of prodrug properties","volume":"5","author":"Salvador","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1158\/1535-7163.MCT-07-2347","article-title":"Kd5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo","volume":"7","author":"Hassig","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.1016\/j.bmcl.2008.10.029","article-title":"Identification of kd5170: A novel mercaptoketone-based histone deacetylase inhibitor","volume":"18","author":"Payne","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3762\/bjoc.9.11","article-title":"Thioester derivatives of the natural product psammaplin a as potent histone deacetylase inhibitors","volume":"9","author":"Baud","year":"2013","journal-title":"Beilstein J. Org. Chem."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2174\/138945012802008973","article-title":"Discovery and mechanism of natural products as modulators of histone acetylation","volume":"13","author":"Salvador","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1073\/pnas.95.7.3356","article-title":"Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase","volume":"95","author":"Kwon","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"22429","DOI":"10.1016\/S0021-9258(18)41547-5","article-title":"Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase","volume":"268","author":"Kijima","year":"1993","journal-title":"J. Biol. Chem."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1021\/np500387h","article-title":"A potent HDAC inhibitor, 1-alaninechlamydocin, from a Tolypocladium sp. induces G2\/M cell cycle arrest and apoptosis in MIA PaCa-2 cells","volume":"77","author":"Du","year":"2014","journal-title":"J. Nat. Prod."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1016\/S0960-894X(02)00754-0","article-title":"Trifluoromethyl ketones as inhibitors of histone deacetylase","volume":"12","author":"Frey","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1016\/j.bmcl.2004.08.016","article-title":"Novel histone deacetylase inhibitors: Cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones","volume":"14","author":"Jose","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/cmdc.201300433","article-title":"The effect of various zinc binding groups on inhibition of histone deacetylases 1\u201311","volume":"9","author":"Madsen","year":"2014","journal-title":"ChemMedChem"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2010-11-318055","article-title":"Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia","volume":"117","author":"Bishton","year":"2011","journal-title":"Blood"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00277-009-0793-8","article-title":"A phase II multiple dose clinical trial of histone deacetylase inhibitor itf2357 in patients with relapsed or progressive multiple myeloma","volume":"89","author":"Galli","year":"2010","journal-title":"Ann. Hematol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1021\/jm0303094","article-title":"Histone deacetylase inhibitors","volume":"46","author":"Miller","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.str.2004.04.012","article-title":"Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases","volume":"12","author":"Somoza","year":"2004","journal-title":"Structure"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"15064","DOI":"10.1073\/pnas.0404603101","article-title":"Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor","volume":"101","author":"Vannini","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"26926","DOI":"10.1074\/jbc.M113.490706","article-title":"Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability","volume":"288","author":"Lauffer","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1021\/ol035056n","article-title":"Phosphorus-based saha analogues as histone deacetylase inhibitors","volume":"5","author":"Kapustin","year":"2003","journal-title":"Org. Lett."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1016\/j.bmc.2005.12.047","article-title":"Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases","volume":"14","author":"Gu","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1073\/pnas.96.8.4592","article-title":"A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors","volume":"96","author":"Saito","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1016\/j.bmcl.2011.06.046","article-title":"Synthesis and biological evaluation of piperamide analogues as HDAC inhibitors","volume":"21","author":"Luo","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bmcl.2013.11.072","article-title":"Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors","volume":"24","author":"Taddei","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1016\/j.bmc.2014.05.001","article-title":"Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors","volume":"22","author":"Tashima","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/1078-0432.CCR-07-0135","article-title":"Clinical and molecular responses in lung cancer patients receiving romidepsin","volume":"14","author":"Schrump","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0092-8674(02)00625-6","article-title":"Apoptosis: A link between cancer genetics and chemotherapy","volume":"108","author":"Johnstone","year":"2002","journal-title":"Cell"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/1535-7163.425.3.4","article-title":"The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells","volume":"3","author":"Zhang","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Bolden, J.E., Shi, W., Jankowski, K., Kan, C.Y., Cluse, L., Martin, B.P., MacKenzie, K.L., Smyth, G.K., and Johnstone, R.W. (2013). HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis., 4.","DOI":"10.1038\/cddis.2013.9"},{"key":"ref_168","first-page":"733","article-title":"Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors","volume":"6","author":"Zhang","year":"2013","journal-title":"Onco. Targets Ther."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"13548","DOI":"10.1074\/jbc.M510023200","article-title":"Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer","volume":"281","author":"Wilson","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e53766","DOI":"10.1371\/journal.pone.0053766","article-title":"Vorinostat induces apoptosis and differentiation in myeloid malignancies: Genetic and molecular mechanisms","volume":"8","author":"Silva","year":"2013","journal-title":"PLoS One"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/86507","article-title":"Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes","volume":"7","author":"Kim","year":"2001","journal-title":"Nat. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"8814","DOI":"10.1158\/0008-5472.CAN-05-4598","article-title":"Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1\u03b1","volume":"66","author":"Qian","year":"2006","journal-title":"Cancer Res."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"14639","DOI":"10.1073\/pnas.1008522107","article-title":"Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair","volume":"107","author":"Lee","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1158\/1078-0432.CCR-04-2088","article-title":"Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity","volume":"11","author":"Munshi","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1158\/0008-5472.CAN-06-3996","article-title":"Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation","volume":"67","author":"Chen","year":"2007","journal-title":"Cancer Res."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"19482","DOI":"10.1073\/pnas.0707828104","article-title":"HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination","volume":"104","author":"Adimoolam","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_177","first-page":"3637","article-title":"The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1\/WAF1 1","volume":"63","author":"Rosato","year":"2003","journal-title":"Cancer Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.semcancer.2006.09.005","article-title":"Thioredoxin in cancer\u2014Role of histone deacetylase inhibitors","volume":"16","author":"Marks","year":"2006","journal-title":"Semin. Cancer Biol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"11700","DOI":"10.1073\/pnas.182372299","article-title":"The histone deacetylase inhibitor saha arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin","volume":"99","author":"Butler","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"8635","DOI":"10.1016\/j.bmc.2008.08.003","article-title":"Molecular modeling studies toward the structural optimization of new cyclopeptide-based HDAC inhibitors modeled on the natural product FR235222","volume":"16","author":"Terracciano","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/cmdc.201300372","article-title":"Discovery of potent HDAC inhibitors based on chlamydocin with inhibitory effects on cell migration","volume":"9","author":"Wang","year":"2014","journal-title":"ChemMedChem"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1021\/jm2001025","article-title":"Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes","volume":"54","author":"Neelarapu","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/jm400390r","article-title":"Discovery of the first histone deacetylase 6\/8 dual inhibitors","volume":"56","author":"Olson","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/07391102.2012.10507409","article-title":"Molecular dynamics simulation study explaining inhibitor selectivity in different class of histone deacetylases","volume":"29","author":"Thangapandian","year":"2012","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"e49327","DOI":"10.1371\/journal.pone.0049327","article-title":"Molecular modeling study on tunnel behavior in different histone deacetylase isoforms","volume":"7","author":"Thangapandian","year":"2012","journal-title":"PLoS One"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1007\/s00894-011-1240-z","article-title":"Exploration of the valproic acid binding site on histone deacetylase 8 using docking and molecular dynamic simulations","volume":"18","year":"2012","journal-title":"J. Mol. Model."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1016\/j.bmc.2010.03.080","article-title":"On the inhibition of histone deacetylase 8","volume":"18","author":"Estiu","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1002\/jcc.23390","article-title":"Ligand release mechanisms and channels in histone deacetylases","volume":"34","author":"Kalyaanamoorthy","year":"2013","journal-title":"J. Comp. Chem."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.apsb.2011.10.002","article-title":"Design, synthesis and biological evaluation of novel histone deacetylase inhibitors based on virtual screening","volume":"1","author":"Lu","year":"2011","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/cmdc.201100007","article-title":"Carbamate prodrug concept for hydroxamate HDAC inhibitors","volume":"6","author":"Schlimme","year":"2011","journal-title":"ChemMedChem"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00044-010-9519-7","article-title":"Discovery of a novel histone deacetylase 8 inhibitor by virtual screening","volume":"21","author":"Zhang","year":"2012","journal-title":"Med. Chem. Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/cmdc.200900500","article-title":"A structure-based virtual screening approach toward the discovery of histone deacetylase inhibitors: Identification of promising zinc-chelating groups","volume":"5","author":"Park","year":"2010","journal-title":"ChemMedChem"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"e1003645","DOI":"10.1371\/journal.ppat.1003645","article-title":"Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke schistosoma mansoni","volume":"9","author":"Marek","year":"2013","journal-title":"PLoS Pathog."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1021\/ml300322n","article-title":"Discovery of a series of thiazole derivatives as novel inhibitors of metastatic cancer cell migration and invasion","volume":"4","author":"Zheng","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1021\/jm500724x","article-title":"Modification and biological evaluation of thiazole derivatives as novel inhibitors of metastatic cancer cell migration and invasion","volume":"57","author":"Zheng","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1021\/jm401939g","article-title":"Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach","volume":"57","author":"Canela","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejmech.2013.10.019","article-title":"Novel toll-like receptor 4 (TLR4) antagonists identified by structure- and ligand-based virtual screening","volume":"70","author":"Svajger","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.bbapap.2012.08.009","article-title":"Energy based pharmacophore mapping of HDAC inhibitors against class I HDAC enzymes","volume":"1834","author":"Kalyaanamoorthy","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1080\/07391102.2013.879073","article-title":"Energy-optimised pharmacophore approach to identify potential hotspots during inhibition of class II HDAC isoforms","volume":"33","author":"Ganai","year":"2015","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jmgm.2010.07.007","article-title":"Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery","volume":"29","author":"Thangapandian","year":"2010","journal-title":"J. Mol. Graph. Model."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.5012\/bkcs.2012.33.6.2063","article-title":"Structure-activity relationship of novel lactam based histone deacetylase inhibitors as potential anticancer drugs","volume":"33","author":"Yang","year":"2012","journal-title":"Bull. Korean Chem. Soc."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.bmcl.2010.12.079","article-title":"Structure and property based design, synthesis and biological evaluation of gamma-lactam based HDAC inhibitors","volume":"21","author":"Choi","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1016\/j.bmcl.2012.04.045","article-title":"Structure and property based design, synthesis and biological evaluation of gamma-lactam based HDAC inhibitors: Part II","volume":"22","author":"Lee","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/med.20200","article-title":"Histone deacetylase inhibitors (HDACIs). Structure\u2014Activity relationships: History and new qsar perspectives","volume":"32","author":"Pontiki","year":"2012","journal-title":"Med. Res. Rev."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"9969","DOI":"10.1021\/jm401225q","article-title":"Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors","volume":"56","author":"Sodji","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1016\/j.bmc.2008.03.050","article-title":"Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group","volume":"16","author":"Chen","year":"2008","journal-title":"Bioorg. Med. Chem."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/20\/3\/3898\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:43:03Z","timestamp":1760215383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/20\/3\/3898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,2]]},"references-count":206,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3]]}},"alternative-id":["molecules20033898"],"URL":"https:\/\/doi.org\/10.3390\/molecules20033898","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,2]]}}}